Biodegradable levofloxacin nanoparticles for sustained ocular drug delivery

Journal of Drug Targeting

Volumn 19, Issue 6, 2011, Pages 409-417

  Gupta, Himanshu ^a,b   Aqil, M ^a   Khar, R K ^a   Ali, Asgar ^a   Bhatnagar, Aseem ^b   Mittal, Gaurav ^b  

^a HAMDARD UNIVERSITY   (India)

^b INSTITUTE OF NUCLEAR MEDICINE AND ALLIED SCIENCES   (India)

Author keywords

scintigraphy; HET CAM; hydration test; Levofloxacin; nanoparticle; ocular; PLGA; transcorneal permeation

Indexed keywords

LEVOFLOXACIN; NANOPARTICLE; POLYGLACTIN; TECHNETIUM 99M;

ANIMAL EXPERIMENT; ANTIBACTERIAL ACTIVITY; ARTICLE; CHORIOALLANTOIS; CONTROLLED STUDY; CORNEA PERMEABILITY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG STABILITY; DRUG TOLERABILITY; ENCAPSULATION; GAMMA SCINTIGRAPHY; INFRARED SPECTROSCOPY; MOLECULAR INTERACTION; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; SUSTAINED DRUG RELEASE; X RAY DIFFRACTION; ZETA POTENTIAL;

ANIMALS; ANTI-BACTERIAL AGENTS; BIOCOMPATIBLE MATERIALS; CALORIMETRY, DIFFERENTIAL SCANNING; CHICKENS; CHORIOALLANTOIC MEMBRANE; CORNEA; DRUG CARRIERS; DRUG STABILITY; GOATS; LACTIC ACID; MICROBIAL SENSITIVITY TESTS; NANOPARTICLES; OFLOXACIN; PARTICLE SIZE; PERMEABILITY; POLYGLYCOLIC ACID; SOLUBILITY; SPECTROPHOTOMETRY, INFRARED; STAPHYLOCOCCUS AUREUS; SURFACE PROPERTIES; X-RAY DIFFRACTION;

EID: 79958842065     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.3109/1061186X.2010.504268     Document Type: Article

References (32)

1. Agnihotri SM, Vavia PR. (2009). Diclofenac-loaded biopolymeric nanosuspensions for ophthalmic application. Nanomedicine, 5, 90-95.
2. Araújo J, Vega E, Lopes C, Egea MA, Garcia ML, Souto EB. (2009). Effect of polymer viscosity on physicochemical properties and ocular tolerance of FB-loaded PLGA nanospheres. Colloids Surf B Biointerfaces, 72, 48-56.
3. Bochot A, Fattal E, Grossiord JL, Puisieux F, Couvereur P. (1998). Characterization of a new ocular delivery system based on a dispersion of liposomes in a thermosensitive gel. Int J Pharm, 162, 119-127. (Pubitemid 28166097)
4. Chaiarini A, Tartarini A, Fini A. (1984). pH solubility relationship and partition coefficient for some anti-inflammatory arylaliphatic acid. Arch Pharm, 317, 268-273. (Pubitemid 14155093)
5. De Campos AM, Diebold Y, Carvaiho ELS, Sanchez A, Alonso MJ. (2004) Chitosan nanoparticles as new ocular drug delivery system: in vitro stability, in vivo fate, and cellular toxicity. Pharm Res, 21, 803-810. (Pubitemid 39011304)
6. De Campos AM, Sánchez A, Gref R, Calvo P, Alonso MJ. (2003). The effect of a PEG versus a chitosan coating on the interaction of drug colloidal carriers with the ocular mucosa. Eur J Pharm Sci, 20, 73-81. (Pubitemid 37103234)
7. Ding S. (1998). Recent developments in ophthalmic drug delivery. Pharm Sci Technol Today, 1, 328-335. (Pubitemid 28526961)
8. Duffy MT, Bloom JN, McNally-Heintzelman KM, Heintzelman DL, Soller EC, Hoffman GT. (2005). Sutureless ophthalmic surgery: a scaffold-enhanced bioadhesive technique. J AAPOS, 9, 315-320. (Pubitemid 41116865)
9. Ewers R, Lieb-Skowron J. (1990). Bioabsorbable osteosynthesis materials. Facial Plast Surg, 7, 206-214.
10. Govender T, Stolnik S, Garnett MC, Illum L, Davis SS. (1999). PLGA nanoparticles prepared by nanoprecipitation: drug loading and release studies of a water soluble drug. J Control Release, 57, 171-185. (Pubitemid 29062869)
11. Gupta H, Aqil M, Khar RK, Ali A, Bhatnagar A, Mittal G. (2009). Sparfloxacin-loaded PLGA nanoparticles for sustained ocular drug delivery. Nanomedicine, 6, 324-333.
12. Gupta H, Aqil M, Khar RK, Ali A, Chander P. (2010). A Single RP-UPLC method for quantification of Levofloxacin in aqueous humour and pharmaceutical dosage forms. J Chromatogra Sci , 48, 484-490.
13. Gupta H, Jain S, Mathur R, Mishra P, Mishra AK, Velpandian T. (2007). Sustained ocular drug delivery from a temperature and pH triggered novel in situ gel system. Drug Deliv, 14, 507-515. (Pubitemid 350135850)
14. Jain RA. (2000). The manufacturing techniques of various drugloaded biodegradable poly(lactide-co-glycolide) (PLGA) devices. Biomaterials, 21, 2475-2490.
15. Kassem MA, Abdel Rahman AA, Ghorab MM, Ahmed MB, Khalil RM. (2007). Nanosuspension as an ophthalmic delivery system for certain glucocorticoid drugs. Int J Pharm, 340, 126-133. (Pubitemid 47043351)
16. Keating GM. (2009). Levofloxacin 0.5% ophthalmic solution: a review of its use in the treatment of external ocular infections and in intraocular surgery. Drugs, 69, 1267-1286.
17. Losa C, Calvo P, Castro E, Vila-Jato JL, Alonso MJ. (1991). Improvement of ocular penetration of amikacin sulphate by association to poly(butylcyanoacrylate) nanoparticles. J Pharm Pharmacol, 43, 548-552.
18. Losa C, Marchal-Heussler L, Orallo F, Vila Jato JL, Alonso MJ. (1993). Design of new formulations for topical ocular administration: polymeric nanocapsules containing metipranolol. Pharm Res, 10, 80-87. (Pubitemid 23020842)
19. Mandal B, Halder KK, Dey SK, Bhoumik M, Debnath MC, Ghosh LK. (2009). Development and physical characterization of chloramphenicol loaded biodegradable nanoparticles for prolonged release. Pharmazie, 64, 445-449.
20. Marchal Heussler L, Fessi H, Devissaguet JP, Hoffman M, Maincent P. (1992). Colloidal drug delivery systems for eye: a comparison of the efficacy of three different polymers. S.T.P. Pharma Sciences, 2, 98-104.
21. McCarron PA, Marouf WM, Quinn DJ, Fay F, Burden RE, Olwill SA, Scott CJ. (2008). Antibody targeting of camptothecin-loaded PLGA nanoparticles to tumor cells. Bioconjug Chem, 19, 1561-1569.
22. Muthu MS, Rawat MK, Mishra A, Singh S. (2009). PLGA nanoparticle formulations of risperidone: preparation and neuropharmacological evaluation. Nanomedicine, 5, 323-333.
23. Paolicelli P, Cerreto F, Cesa S, Feeney M, Corrente F, Marianecci C, Casadei MA. (2008). Influence of the formulation components on the properties of the system SLN-dextran hydrogel for the modified release of drugs. J Microencapsul, 25, 1-10.
24. Pleyer U, Lutz S, Jusko W, Nguyen K, Narawane M, Rückert D, Mondino BJ, Lee VH. (1993). Ocular absorption of topically applied FK506 from liposomal and oil formulations in rabbit eye. Invest Ophthalmol Vis Sci, 34, 2737-2742. (Pubitemid 23232483)
25. Schoenwald RD, Stewart P. (1980). Effect of particle size on ophthalmic bioavailability of dexamethasone suspensions in rabbits. J Pharm Sci, 69, 391-394. (Pubitemid 10079746)
26. Reis CP, Ribeiro AJ, Veiga F, Neufeld RJ, Damgé C. (2008). Polyelectrolyte biomaterial interactions provide nanoparticulate carrier for oral insulin delivery. Drug Deliv, 15, 127-139. (Pubitemid 351302237)
27. Feng S, Huang G. (2001). Effects of emulsifiers on the controlled release of paclitaxel (Taxol) from nanospheres of biodegradable polymers. J Control Release, 71, 53-69. (Pubitemid 32195441)
28. Spielmann H. (1997). Ocular irritation. In: Castle JV, Gomez MJ, eds. In Vitro Methods in Pharmaceutical Research (pp. 265-87). San Diego, CA: Academic Press.
29. Sultana Y, Aqil M, Ali A. (2006). Ion-activated, Gelrite-based in situ ophthalmic gels of pefloxacin mesylate: comparison with conventional eye drops. Drug Deliv, 13, 215-219.
30. Suri SS, Fenniri H, Singh B. (2007). Nanotechnology-based drug delivery systems. J Occup Med Toxicol, 2, 16.
31. Surti N, Naik S, Bagchi T, Dwarkanath BS, Misra A. (2008). Intracellular delivery of nanoparticles of an antiasthmatic drug. AAPS PharmSciTech, 9, 217-223.
32. Vega E, Gamisans F, García ML, Chauvet A, Lacoulonche F, Egea MA. (2008). PLGA nanospheres for the ocular delivery of flurbiprofen: drug release and interactions. J Pharm Sci, 97, 5306-5317.